Answers are grounded in this paper and cite their sources.
A placebo was substituted for maintenance antiparkinson drug in 41 patients who had been given this medication for the control of phenothiazine-induced extra-pyramidal reactions. These reactions did not recur in 24 of the 41 patients (59%). Although recurrence rates will vary with different clinical situations, it is probable that a large proportion of patients do not require maintenance antiparkinson drug for continued clinical control of phenothiazine-induced extra-pyramidal reactions. Trials are recommended to determine which patients should or should not continue to receive maintenance antiparkinson drug.
No takes yet. Share an insight, caveat, or question.
Mandel et al. (1961) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: